Kristene Whitmore, MD
Urogynecology and Reconstructive Pelvic Surgery · Cherry Hill, NJNPI 1407905383
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.1%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 60.9% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $8,261, 5.3 times the $1,565 reported in 2019.
Across 132 payments — averaging $99.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Medtronic$4K
- Coloplast$572
- Boston Scientific$355
- Astellas Pharma US Inc$254
- Sumitomo Pharma America, Inc.$86
- plus $227 from 6 others
Across 1 payment — averaging $325.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$325
What the payments were for
- Consulting fees$7,75059%
- Travel & lodging$400%
- Food & beverage$5,14639%
- Education$1791%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 10 | $7,986 |
| Medtronic(2 entities) | 82 | $3,635 |
| Coloplast | 11 | $572 |
| Boston Scientific | 6 | $355 |
| Astellas Pharma US Inc | 7 | $254 |
| Sumitomo Pharma America, Inc. | 5 | $86 |
| Bluewind Medical | 2 | $82 |
| Therapeuticsmd, Inc. | 3 | $42 |
| Axonics, Inc. | 1 | $34 |
| Urovant Sciences Inc | 2 | $29 |
| Renovia Inc | 2 | $27 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$1,959
- GENERAL PELVIC ORGAN PROLAPSE$146
- Axonics$133
- AXIS$114
- Orilissa$109
How this compares
$13,115 in reported general payments places this provider in the 85th percentile of 35 urogynecology and reconstructive pelvic surgery providers in New Jersey.
See all urogynecology and reconstructive pelvic surgery providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 86 | $65,862 |
| GemtesaVibegron | 60 | $43,449 |
| Estradiol | 198 | $16,278 |
| Methenamine Hippurate | 101 | $5,226 |
| Potassium Citrate ErPotassium Citrate | 23 | $2,049 |
| Fosfomycin Tromethamine | 11 | $2,001 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 112 | $1,435 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $683 |
| NitrofurantoinNitrofurantoin Macrocrystal | 21 | $668 |
| Phenazopyridine Hcl | 16 | $561 |
| Solifenacin Succinate | 29 | $542 |
| Oxybutynin Chloride | 12 | $436 |
| Amitriptyline Hcl | 33 | $363 |
| Hydroxyzine Hcl | 20 | $353 |
| Metronidazole | 11 | $339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $254 | $65,86286 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $86 | $43,44960 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 35 urogynecology and reconstructive pelvic surgery providers in New Jersey.
Other urogynecology and reconstructive pelvic surgery in Cherry Hill
- Alexander BergerCherry Hill$14K
- Nina BhatiaManalapan$77K
- Debra FromerHackensack$50K
- Donald DebrakeleerPennington$36K
- Uzma ChaudhryTrenton$14K
- Betsy GreenleafHowell$11K
- Sandy NosseirMarlton$11K
- Gary MironeCape May Court House$9K
- Anna PancheshnikovVoorhees$8K
- Patricia ZahnerMoorestown$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.